Product Details

Panitumumab is a fully human monoclonal antibody (IgG2) that specifically targets the epidermal growth factor receptor (EGFR), also known as ErbB-1 or HER1. As a biosimilar to the FDA-approved therapeutic panitumumab, it is designed to inhibit EGFR signaling, thereby preventing tumor growth and proliferation in EGFR-expressing cancers. Panitumumab binds to the extracellular domain of EGFR, blocking its interaction with natural ligands such as EGF and TGF-α. This inhibition disrupts downstream signaling pathways, including the RAS-RAF-MEK-ERK and PI3K-AKT pathways, leading to reduced tumor cell proliferation, angiogenesis, and survival.